CDSCO approves CoSara Diagnostics’ five test kits for TB, Hepatitis B & C, Malaria & HPV

New Delhi: CoSara Diagnostics has obtained regulatory clearance for five tests to be manufactured and sold as in-vitro diagnostics (IVDs) from their facility in Ranoli, India. As per the company, its Saragene™ tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) have met the requirements of the Central Drug Standard Control Organization (CDSCO) Medical Device Rules 2017, to be manufactured and sold as IVDs.

CoSara is a joint venture for manufacturing of Co-Diagnostics, Inc.a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and Synbiotics Pvt Ltd, a group company of Asence Inc, a U.S. company that specializes in supplying pharmaceutical products to international markets across 35 countries.

CDSCO approval under File no. 29/Misc./3/2017-DC (292), was granted following the completion of the CoSara manufacturing facility and a comprehensive inspection of the location, presentation of the technology, quality system, procedures, product validation data and performance evaluation by an independent NABL and CAP-accredited laboratory.

The licenses and regulatory clearance allow CoSara for the first time to manufacture and sell the tests for the detection of the respective pathogens and microorganisms.

The CoSara plant is one of the first facilities for manufacturing molecular diagnostics in India and has been designed to meet both current and future requirements for medical device manufacturing, which are expected to be implemented by the Indian government.

CoSara distributors have begun taking pre-orders for the five IVDs, and the Company expects sales to ramp quickly. The JV has the exclusive manufacturing rights in India for the complete menu of Co-Diagnostics infectious disease molecular diagnostics kits, designed by Co-Diagnostics using their patented CoPrimer™ technology platform.

Additional tests which are expected to be submitted to the CDSCO for approval consist of those for drug-resistant tuberculosis, HIV and more, including a multiplexed panel specifically for blood-bank screening.

Dwight Egan, Company CEO, remarked, “India is soon to become the largest healthcare market on the planet and the best place for CoPrimer-powered products to be manufactured and distributed is from within the country itself. Being able to sell fully approved IVDs to this market represents the next stage in our growth as we establish Co-Diagnostics to be a leading innovator of high-quality, affordable diagnostics solutions. We are excited to be taking this next step in our growth with such a distinguished partner and are eager to see returns on the time and effort we have spent to get to this point.”

“We are honored to be the manufacturer of the first indigenous PCR-based diagnostic kits in India,” said Mr. Mohal Sarabhai, CEO of Synbiotics. “Our team has worked tirelessly this year, ensuring the facility and procedures meet or exceed the requirements to fulfill our mandate of providing cutting-edge molecular diagnostics technology to India. The goals of the ‘make in India’ initiative aligns perfectly with those of CoSara, and we look forward to serving not only the Indian market but to receiving the CE markings and other necessary regulatory approvals that will allow CoSara Diagnostics to expand on a global scale.”